North America Kidney Cancer Therapeutics & Diagnostics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

The North America Kidney Cancer Therapeutics & Diagnostics Market is segmented by Cancer Type, Component (Drugs and Diagnostics) and Geography.

Market Snapshot

Market Snapshot1
Study Period: 2018 - 2026
Base Year: 2020
CAGR: 5.8 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The North America Kidney Cancer Therapeutics & Diagnostics Market is expected to register a CAGR of 5.8% during the forecast period. The major factors driving the growth of the market in the North America region is due to the rising number of kidney cancer cases and increased R&D expenditure of the pharmaceutical companies.

According to GLOBOCAN 2018, in 2018, there were about 60,336 new kidney cancer cases and the mortality was approximately 15,333 cases in the United States.

Furthermore, changes in lifestyle, excessive smoking, increased consumption of alcohol, and a rise in obesity because of sedentary life routines lead to the growing incidence of the disease. Thus, owing to the above factors the North America kidney cancer therapeutics & diagnostics market is expected to significant growth over the forecast period.

Scope of the report

As per the scope of the report, kidney cancer is a type of cancer that starts in kidney cells. The kidney cancer therapeutics and diagnostics involve therapy and diagnostics methods that are used for the treatment of renal cancer. The North America kidney cancer therapeutics & diagnostics market is segmented by cancer type, component and geography.

Report scope can be customized per your requirements. Click here.

Key Market Trends

Clear cell RCC Segment is Expected to Hold Major Market Share in the North America Kidney Cancer Therapeutics & Diagnostics Market

Clear cell renal cell carcinoma, or ccRCC, is a type of kidney cancer. Clear cell renal cell carcinoma is also called conventional renal cell carcinoma. Clear cell renal cell carcinoma is named after how the tumor looks under the microscope. The cells in the tumor look clear, like bubbles.

As per the National Cancer Institute of the United States, in adults, ccRCC is the most common type of kidney cancer and makes up about 80% of all renal cell carcinoma cases. ccRCC is more common in adults than in children. Renal cell carcinoma makes up 2% to 6% of childhood and young adult kidney cancer cases.

For people without symptoms, these tumors can be discovered if the person has an imaging test as well. Another method to detect ccRCC is biopsy. To check if the tumor is ccRCC, the physician performs a biopsy, taking a small sample from the tumor with a needle. The sample is studied under the microscope to see what kind of tumor it is.

Some targeted therapies that are used to treat clear cell renal carcinoma include cabozantinib, axitinib, sunitinib, sorafenib, and pazopanib. Hence, with high prevalence of the disease and presence of diagnostic procedures and treatment therapies, the segment is expected to witness growth.

NA key trend 1.png

To understand key trends, Download Sample Report

Competitive Landscape

The North America Kidney Cancer Therapeutics & Diagnostics Market is moderately consolidated competitive. Product innovation and ongoing R&D activities to develop advanced technologies has helped in boosting the growth of the market. Some of the companies which are currently dominating the market are Bayer AG, F. Hoffmann-La Roche Ltd, Novartis AG, Pfizer Inc, Abbott Laboratories, Amgen Inc, and Seattle Genetics.

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Assumptions

    2. 1.2 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Rising Number of Kidney Cancer Cases

      2. 4.2.2 Increased R&D Expenditure of Pharmaceutical Companies

    3. 4.3 Market Restraints

      1. 4.3.1 High Cost Associated with Treatment

      2. 4.3.2 Preference for Generic Drugs

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Cancer Type

      1. 5.1.1 Clear cell RCC

      2. 5.1.2 Papillary RCC

      3. 5.1.3 Chromophobe RCC

      4. 5.1.4 Urothelial carcinoma/Transitional cell carcinoma

      5. 5.1.5 Other Kidney cancers (Wilms tumor, Renal sarcoma, Collecting duct RCC)

    2. 5.2 By Component

      1. 5.2.1 Drugs

        1. 5.2.1.1 Therapeutic Class

          1. 5.2.1.1.1 Targeted Therapy

          2. 5.2.1.1.2 Immunotherapy

          3. 5.2.1.1.3 Other Therapeutic Class

        2. 5.2.1.2 Pharmacologic Class

          1. 5.2.1.2.1 Angiogenesis Inhibitors

          2. 5.2.1.2.2 Monoclonal Antibodies

          3. 5.2.1.2.3 mTOR Inhibitors

          4. 5.2.1.2.4 Cytokine Immunotherapy (IL-2)

      2. 5.2.2 Diagnostics

        1. 5.2.2.1 Biopsy

        2. 5.2.2.2 Imaging Tests

        3. 5.2.2.3 Blood Tests

        4. 5.2.2.4 Other Diagnostics

    3. 5.3 Geography

      1. 5.3.1 North America

        1. 5.3.1.1 United States

        2. 5.3.1.2 Canada

        3. 5.3.1.3 Mexico

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Pfizer Inc

      2. 6.1.2 F. Hoffmann-La Roche Ltd

      3. 6.1.3 Bayer AG

      4. 6.1.4 Novartis AG

      5. 6.1.5 Amgen Inc

      6. 6.1.6 Abbott Laboratories

      7. 6.1.7 Cerulean Pharma Inc

      8. 6.1.8 Eisai co Ltd

      9. 6.1.9 Seattle Genetic

      10. 6.1.10 GlaxoSmithKline PL

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The North America Kidney Cancer Therapeutics & Diagnostics Market market is studied from 2018 - 2026.

The North America Kidney Cancer Therapeutics & Diagnostics Market is growing at a CAGR of 5.8% over the next 5 years.

Pfizer Inc, F. Hoffmann-La Roche Ltd, Bayer AG, Novartis AG, Amgen Inc are the major companies operating in North America Kidney Cancer Therapeutics & Diagnostics Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!